-
Mashup Score: 3Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Latest Headlines, PathologyTweet
-
Mashup Score: 9Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Latest Headlines, PathologyTweet
-
Mashup Score: 0Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 4Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Latest Headlines, PathologyTweet
-
Mashup Score: 2Exploring adoption rate of 2022 ICC and 2022 WHO Myeloid and Lymphoid Neoplasm Classification in the US - 1 year(s) ago
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.ccf.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Only ~2 weeks left to share your thoughts, please complete if you didn’t before ➡️ https://t.co/pg7OA2CdNs ➡️We are looking to get everybody opinion #mmsm #hemeTwitter #hemePath #OncTwitter #PathTwitter Please share with colleagues 🙏 the more response we get the better https://t.co/wqQ9EddKc7